Novartis AG downgraded by BofA Securities with a new price target
$NVS
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded Novartis AG from Buy to Neutral and set a new price target of $130.00 from $135.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | Buy → Neutral | UBS | |
| 2/12/2025 | Underweight | Morgan Stanley | |
| 2/4/2025 | Hold → Buy | Deutsche Bank | |
| 12/4/2024 | Hold → Reduce | HSBC Securities | |
| 9/11/2024 | $135.00 → $130.00 | Buy → Neutral | BofA Securities |
| 9/5/2024 | Buy → Neutral | Goldman | |
| 9/3/2024 | Buy → Hold | Jefferies | |
| 7/19/2024 | Buy → Hold | Deutsche Bank |